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Abstract
Recently, a syndrome of Mutant INS-gene-induced Diabetes of Youth (MIDY, derived from one of 26 distinct mutations) has
beenidentifiedasacauseofinsulin-deficientdiabetes,resultingfromexpressionofamisfoldedmutantproinsulinproteininthe
endoplasmic reticulum (ER) of insulin-producing pancreatic beta cells. Genetic deletion of one, two, or even three alleles
encoding insulin in mice does not necessarily lead to diabetes. Yet MIDY patients are INS-gene heterozygotes; inheritance of
even one MIDYallele,causesdiabetes.Although afavoredexplanationforthe onsetof diabetesisthatinsurmountableERstress
and ER stress response from the mutant proinsulin causes a net loss of beta cells, in this report we present three surprising and
interlinked discoveries. First, in the presence of MIDY mutants, an increased fraction of wild-type proinsulin becomes recruited
into nonnative disulfide-linked protein complexes. Second, regardless of whether MIDY mutations result in the loss, or creation,
of an extra unpaired cysteine within proinsulin, Cys residues in the mutant protein are nevertheless essential in causing
intracellular entrapment of co-expressed wild-type proinsulin, blocking insulin production. Third, while each of the MIDY
mutants induces ER stress and ER stress response; ER stress and ER stress response alone appear insufficient to account for
blockade of wild-type proinsulin. While there is general agreement that ultimately, as diabetes progresses, a significant loss of
beta cell mass occurs, the early events described herein precede cell death and loss of beta cell mass. We conclude that the
molecular pathogenesis of MIDY is initiated by perturbation of the disulfide-coupled folding pathway of wild-type proinsulin.
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Introduction
Insulinopathies classically have been described as rare mono-
genic causes of adult diabetes mellitus caused by point mutations
leading to selective amino-acid substitution within the mutant
insulin molecule or its precursor, involving impaired sorting to
secretory granules, endoproteolytic conversion to insulin, or
binding to insulin receptors [1,2,3]. More recent are numerous
reports of insulin-deficient diabetes caused by heterozygous
mutations in the insulin gene [4,5,6,7,8]. These mutations account
for a significant subset of cases of permanent neonatal-onset
diabetes mellitus [9], a syndrome referred to as Mutant INS-gene
induced Diabetes of Youth (MIDY) [10,11].
The discovery of MIDY has stimulated renewed interest in the
earliest steps of the insulinbiosynthesis pathway [12]. Upon delivery
to the endoplasmic reticulum (ER), preproinsulin undergoes co-
translational translocation with cleavage of the signal peptide.
Folding is initiated upon translocation into the ER lumen;
acquisition of proinsulin tertiary structure [10] is coupled to the
catalyzed oxidation of the hormone’s three evolutionarily conserved
disulfide bonds [13]. Proinsulin can form zinc-independent dimers
and undergo transport to the Golgi complex where zinc-stabilized
hexamers are thought to form before their proteolytic processing in
newly-forming insulin secretory granules [14].
MIDY mutations impair proinsulin folding; such products of the
mutant INS-gene allele are deficient in producing insulin
[4,5,15,16,17]. Genetic deficiency of insulin expression can cause
diabetes [18], but MIDY patients are heterozygotes and INS-gene
haploinsufficiency is not itself a sufficient basis for diabetes, at least
not in mice [19,20,21,22]. Thus, it is not clear why MIDY patients
— all of whom co-express wild-type proinsulin alongside the
mutant proinsulin— should develop diabetes. A prevailing thought
is that chronic ER stress with unremitting ER stress response
activation triggers pancreatic beta cell death with a loss of
pancreatic beta cell mass [23,24,25]. Indeed, there is little dispute
that ultimately, after diabetes progresses in both humans and
animal models, there is a loss of beta cell mass [26]; yet debate
continues about whether impaired beta cell function precedes or
follows the loss of beta cell mass [27]. Akita mice transmit
heterozygous inheritance of a single MIDY mutant proinsulin-
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Though ultimately, Akita diabetic mice end up with few if any beta
cells [29], a recent study reports that at the time of initial onset of
the hyperglycemia of MIDY, these animals have expansion of their
beta cell mass from beta cell hyperplasia within each islet [30].
In the present study we examine the initial molecular
mechanism of MIDY and find that it involves misfolded mutant
copies of nascent proinsulin recruiting wild-type proinsulin into
misfolded disulfide-linked protein complexes and thereby inhibit-
ing wild-type insulin production.
Results
MIDY mutants, blocked in export, engage in disulfide-
linked protein complexes
Following cleavage of the preproinsulin signal peptide (residues 1–
24), three domains of proinsulin follow sequentially (Table S1): the B-
chain (residues 1–30), flanking dibasic cleavage sites plus C-peptide (-2;
residues 1–31; +2), and A-chain (residues 1–21). Proper folding of
proinsulin requires formation of three evolutionarily-conserved
disulfide bridges (Table S1, upper left diagram): C(B7)-C(A7), C(B19)-
C(A20), and C(A6)-C(A11), while the C-peptide ordinarily has no
cysteines and remains disordered [31,32]. Three insulinopathies,
F(B24)S, F(B25)L, and V(A3)L, are classically associated with adult-
onset diabetes (Table S1). Although proinsulin-F(B24)S was less
efficient in export, all three were secreted significantly (Figure S1A, B).
Further, the human proinsulin-G(C28)R variant, reported as a
possible cause of disease [7], was exported normally (Figure S1A,
B), and led to normal insulin production in the Min6 pancreatic beta
cell line (not shown) whereas MIDY mutants [11] (a subset from the list
in Table S1) were largely blocked in secretion (Fig. S1A, B).
Many MIDY mutants involve gain or loss of a cysteinyl residue
[4,5,6,7,8], and proinsulin-C(A7)Y (causing diabetes in the Akita
mouse) is the most studied of these [15,23,33,34,35,36]. Although
Izumi et al. reported no evidence for abnormally increased
intracellular levels of abnormally disulfide-bonded protein in cells
expressing proinsulin-C(A7)Y [34], we re-visited this question with a
simple assay to quantify recovery by Tris-tricine-urea-SDS-PAGE of
the native proinsulin disulfide isomer band visualized under
nonreducing conditions, normalized to total proinsulin visualized
under reducing conditions (which abrogates both inter- and
intramolecular disulfides and thereby generates a single proinsulin
band). While more than half of newly-synthesized wild-type
proinsulin [or mutants classically associated with adult-onset
diabetes, or the proinsulin-G(C28)R variant] were recovered as the
native disulfide isomer, only one third of MIDY mutants
(35.1%67.2%) could be recovered as any kind of monomeric isomer
(Fig. 1A upper panels). By 4 h after synthesis, some loss of misfolded
proinsulin may have occurred by ER-associated degradation; more
importantly, of residual MIDY proinsulin, the relative recovery
became vanishingly small under nonreduced (compared to reduced)
conditions (Fig. 1A lower panel, quantified in Fig. 1B). These data
Figure 1. MIDY proinsulins form abnormally increased amounts of disulfide-linked protein complexes. 293T cells were transfected with
vector expressing preproinsulin wild type (‘WT’) or preproinsulin missense mutants in which the described mutation is within the B-chain, C-peptide,
or A-chain. At 40 h post-transfection, cells were pulse-labeled with
35S-amino acids for 1 h and then chased for the times indicated. For completeness,
chase media and cell lysates were mixed, but none of the MIDY proinsulins are appreciably secreted (see Figure S1). A. At both time points, samples
were immunoprecipitated with anti-insulin followed by Tris-tricine-urea-SDS-PAGE under both nonreducing (gels on left) and reducing conditions
(gels on right), followed by fluorography. B. The fractional recovery of the native isoform of newly-synthesized proinsulin (fastest migrating band
under nonreduced conditions) at 4 h of chase was compared against the recovery from the same sample under reducing conditions (considered
to represent total at that chase time). The relative recovery for proinsulin-WT served as a positive control (ie, set to 100%). Results are expressed as
mean 6 s.d. from two independent experiments.
doi:10.1371/journal.pone.0013333.g001
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intermolecular disulfide-linked protein complexes as well as
abnormal intramolecular disulfide isomers. As described further
(below), this aberrant behavior also occurs in vivo as it is found in
pancreatic islets of Akita mice, a mouse model of MIDY.
Designing a mutant proinsulin that cannot engage in
intermolecular disulfide-linked protein complexes
To design a misfolded, nonsecreted mutant proinsulin incapable
of engaging in intermolecular disulfide bonds, we introduced
missense substitutions for all 6 Cys residues to create proinsulin-
DelCys [or simply ‘‘DelCys’’ bearing the Akita-like C(A7)Y but also
containing C(B7)S, C(B19)S, C(A20)S, C(A6)M, and C(A11)M
mutations that permit metabolic labeling with
35S-methionine].
Not surprisingly, DelCys was completely defective for protein
secretion from cells to medium, but unlike proinsulin-C(A7)Y,
DelCys was quantitatively recovered upon nonreducing tris-
tricine-urea-SDS-PAGE, and its gel mobility was unchanged
under nonreducing versus reducing conditions (Figs. 2A, B).
Bearing no Cys residues, DelCys should not be able to be
alkylated with AMS, a maleimide derivative that irreversibly adds
0.5 kD of molecular mass for each thiol modified [37]. We
compared the (lack of) alkylation of DelCys to that of the
proinsulin-C(A7)Y MIDY mutant with its odd number of Cys
residues. At different times after synthesis, immunoprecipitates of
metabolically labeled proinsulin mutants were divided in half and
either reacted or mock-treated with AMS. Newly-synthesized
proinsulin-C(A7)Y should have at least one free thiol available
unless it uses an unpaired cysteine to engage in an intermolecular
disulfide bond, in which case it cannot react with AMS.
Immediately after synthesis, approximately half of the C(A7)Y
molecules had already consumed available cysteine thiols (Fig. 2C
gel at left; quantified at right). Over the next 4 h, the remaining
proinsulin-C(A7)Y had consumed nearly all free thiols, Fig. 2C).
Addition of the proteasome inhibitor lactacystin during these 4 h
increased final recovery, but the proinsulin-C(A7)Y still engaged in
disulfide-linked complexes as judged by a loss of free thiols
(Fig. 2C). By contrast, DelCys showed no reactivity with AMS at
any time (Fig. 2C and data not shown), consistent with an inability
to engage in intermolecular disulfide-linked protein complexes.
Further, we confirmed AMS modification of proinsulin-C(A7)Y in
metabolically-labeled islets from Akita mice, whereas no AMS
modification of labeled proinsulin was observed in islets from wild-
type mice (not shown).
Dominant-negative inhibition of wild-type proinsulin
trafficking is a distinguishing feature of MIDY mutants
We previously reported that proinsulin-C(A7)Y can engage co-
expressed nonmutant proinsulin in protein complexes within the
ER [36]; such a mechanism could underlie the dominant-negative
inhibition of wild-type proinsulin transport that has been observed
by us and others [15,16,29]. We wished to compare the extent to
which wild-type proinsulin trafficking from the ER could be
blocked by MIDY mutants that have substitutions in residues other
than a cysteine. In the rat INS832/13 beta cell line that co-
synthesizes wild-type human insulin, we analyzed by human-
specific radioimmunoassay the content of mature human insulin
(produced in secretory granules [38]) as an indicator of the ability
of human proinsulin to reach post-ER compartments. Like for
proinsulin-C(A7)Y, expression in trans of mouse proinsulin-H(B5)D
or L(B11)P inhibited production of mature human insulin despite
the fact that these MIDY mutant proinsulins neither added nor lost
Figure 2. Misfolded proinsulin with or without free cysteine thiols. A. 293T cells transiently expressing mouse proinsulin-WT (‘WT’) or
proinsulin-DelCys (‘DelCys’) were pulse-labeled with
35S-amino acids for 1 h without chase. Cells were lysed and immunoprecipitated with anti-
insulin, followed by Tris-tricine-urea-SDS-PAGE under both nonreducing and reducing conditions as indicated, followed by fluorography.
‘‘N’’=proinsulin with native disulfide pairs; ‘‘I’’=proinsulin disulfide isomer(s). Note that proinsulin-DelCys has identical gel mobility under
nonreducing and reducing conditions. B. 293T cells transiently expressing empty vector, proinsulin-WT, proinsulin-C(A7)Y, or proinsulin-DelCys were
pulse-labeled with
35S-amino acids for 1 h and chased for 1 h. Cell lysates (‘C’) and chase media (‘M’) were immunoprecipitated with anti-insulin and
analyzed as in A. C. 293T cells transiently expressing proinsulin-C(A7)Y or proinsulin-DelCys were pulse-labeled with
35S-amino acids for 1 h and
chased in complete medium for the times indicated. For one sample, 10 mM lactacystin (‘Lac’) was added to the chase medium bathing transfected
cells. At each chase time, cells were lysed, immunoprecipitated with anti-insulin, and the immunoprecipitates incubated with or without AMS as
described in Methods, and analyzed by reducing Tris-Tricine-urea-SDS-PAGE and fluorography. As a fraction of all proinsulin bands recovered per
lane, thiol-consumed (nonreactive) and thiol-available (AMS reactive) subfractions of newly-synthesized proinsulin-C(A7)Y were quantified by
scanning densitometry; the average and range from two independent such experiments is shown at right. Note that proinsulin-DelCys has no
reactivity with AMS.
doi:10.1371/journal.pone.0013333.g002
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entrapped in the secretory pathway (Fig. 2B), DelCys was largely
ineffective in blocking production of wild-type human insulin from
a co-expressed allele (Fig. 3A, right), and unlike MIDY mutants
[such as proinsulin-C(A7)Y and G(B23)V], DelCys could not
effectively inhibit secretion of co-expressed wild-type human
insulin (Fig. 3B). [As expected, proinsulin mutants F(B25)L and
V(A3)L, classically associated with adult-onset diabetes, were
unable to block human insulin production, whereas proinsulin-
F(B24)S exhibited an intermediate phenotype (Fig. 3A)].
To ensure that the observed results did not reflect mutant
proinsulin action within the secretory granule compartment
[16,17], we used a human-specific proinsulin radioimmunoassay
in 293T cells that make neither insulin nor secretory granules, to
examine secretion of wild-type human proinsulin co-expressed in
the presence of mouse wild-type or mutant proinsulins. Although
none bears an extra or missing Cys residue, each of the MIDY
proinsulins tested [bearing substitutions H(B5)D, G(B8)R,
L(B11)P, R(B22)Q, or G(B23)V] severely inhibited secretion of
co-expressed human proinsulin-WT. Despite being even more
severely unstructured, proinsulin-DelCys showed no significant
dominant-negative behavior (Fig. 3C), which corresponds with its
inability to form aberrant intermolecular disulfide bonds (Fig. 2).
Together, the data strongly suggest that dominant-negative effects
on the export of co-expressed proinsulin-WT does not require an
odd number of Cys residues in the primary structure of MIDY
mutants [e.g., H(B5)D, G(B8)R, L(B11)P, R(B22)Q, G(B23)V] yet
cysteine exposure in the proinsulin folding pathway is linked to
dominant-negative disease.
In order to simultaneously follow wild-type proinsulin bystander
molecules while monitoring general ER export, we co-expressed
proinsulins of distinct molecular mass (that could be resolved by
SDS-PAGE) while simultaneously examining a1-antitrypsin [an
unrelated secretory protein that is well expressed in pancreatic
beta-cells [39]]. To introduce a small difference in molecular mass
into wild-type human proinsulin, a myc-epitope tag was
bioengineered into the C-peptide to create ‘hProCpepMyc’ (also
called ‘tagged Proins-WT’, Fig. 4A). Tagged proinsulin-WT is
efficiently secreted from cells and is immunoprecipitated equally
well with anti-insulin or anti-myc antibodies (Fig. S1C, and
Fig. 4B). 293T cells expressing tagged proinsulin-WT, untagged
proinsulin mutant, and a1-antitrypsin were split into two wells for
pulse-labeling. One well was lysed at the zero chase time (lanes
marked ‘‘0’’) and the second chased before cell lysates (‘‘C’’) and
media (‘‘M’’) were immunoprecipitated with anti-insulin and anti-
a1-antitrypsin, respectively (Fig. 4C). Notably, when plasmid
encoding untagged proinsulin was eliminated and replaced by
empty vector, only one proinsulin band was immunoprecipitated,
corresponding to tagged proinsulin-WT, and the newly-synthe-
sized proinsulin was predominantly secreted (Fig. 4C upper left).
When tagged proinsulin-WT was co-expressed either with
untagged proinsulin-WT or the G(C28)R variant or mutants
classically associated with adult-onset diabetes, both sets of
proinsulins were predominantly secreted (Fig. 4C). However,
Figure 3. Effect of mutant proinsulins on insulin storage derived from co-expressed nonmutant proinsulin in pancreatic beta cells
(and effect of mutant proinsulins on proinsulin export in 293T cells). A. INS832/13 cells, which co-store human insulin in secretory granules,
were transiently transfected with pCMS-GFP to co-express mouse preproinsulins (as indicated) and cytosolic GFP. Transfected cells were recovered
after 48 h by fluorescence-activated cell sorting and were extracted with acid-ethanol. A human insulin-specific radioimmunoassay was used to
measure hormone storage in mature secretory granules, normalized to cell number. When mouse proinsulin-WT was expressed, the amount of
human insulin stored served as a positive control (ie, set to 100%). Results shown are the mean 6 s.d. in at least three independent experiments.
*p,0.05 compared with mouse proinsulin-WT. B. INS-1 cells were co-transfected with wild-type human preproinsulin and wild-type or mutant
mouse preproinsulin. Transfected cells were incubated for 28 h with fresh medium before collection for measurement of secreted human insulin
using human insulin specific radioimmunoassay. C. 293T cells were co-transfected to express 1) human proinsulin-WT and co-express 2) mouse
proinsulin-WT or missense mutants in which the described mutation is within the B-chain, C-peptide, A-chain, or proinsulin-DelCys at a plasmid ratio
of 1 : 2. Beginning at 24 h post-transfection, cells were incubated for 16 h with high-glucose DMEM plus 10% FBS. Media were collected and a human
proinsulin-specific radioimmunoassay was used to measure secretion of co-expressed human proinsulin-WT. When mouse proinsulin was replaced by
empty vector, the amount of human proinsulin-WT secretion served as a positive control (ie, set to 100%). Medium collected from 293T cells
expressing only mouse proinsulin-WT served as a negative control for the specificity of the human proinsulin radioimmunoassay (while independent
measurements not shown proved ample secretion of rodent proinsulin-WT in these samples). Results are expressed as mean 6 s.d. from at least three
independent experiments. *p,0.05 compared with mouse proinsulin-WT.
doi:10.1371/journal.pone.0013333.g003
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[C(A7)Y or L(B11)P] were not only defective for secretion but also
inhibited secretion of tagged proinsulin-WT (Fig. 4C). Important-
ly, co-expressed a1-antitrypsin continued to acquire Golgi sugar
modifications and to exhibit efficient secretion from these same
cells expressing MIDY mutants (Fig. 4C bottom panels). These data
indicate that early toxic effects of MIDY proinsulin expression act
via blockade of Proins-WT transport prior to loss of cells from cell
death, because the cells are actively synthesizing proteins and
because the general secretory pathway is functionally operational
despite blockade of proinsulin-WT transport. Moreover, untagged
DelCys, while completely blocked in its secretion, could not block
the predominant secretion of tagged proinsulin-WT, underscoring
yet again that at least one Cys residue is needed for the dominant-
negative phenotype (Fig. 4C).
To determine if the myc-epitope tag contributes to impaired
trafficking of co-expressed wild-type proinsulin, we compared
results when transferring the tag to the mutant partner. Regardless
of tag, the proinsulin-C(A7)Y mutant inhibited wild-type proinsu-
lin secretion; and regardless of tag, DelCys could not inhibit wild-
type proinsulin secretion (Fig. 5A). It is thus irrelevant which
partner has the myc tag.
If dominant-negative inhibition of proinsulin export by co-
expressed MIDY mutants is caused by recruitment of proinsulin-
WT into abnormal disulfide-linked protein complexes, then a
selective defect in recovery of native proinsulin-WT would be
expected under nonreducing conditions. Indeed, we found that
recovery of the native isomer of untagged wild-type proinsulin
(detected under nonreducing–‘NR’ conditions) was inhibited the
most in cells co-expressing MIDY proinsulins (compare bands
connected by blue lines in Fig. 5B; data from three independent
experiments are quantified in the graph below the gel). To examine the
pathophysiological significance of this finding, we examined the
islets of male Akita mice [in which it is well established that at early
stages of the disease, islet beta-cells remain abundant and
proinsulin translation per islet is either normal or actually
increased despite that insulin production per islet is dramatically
decreased [29,30,33,36,40]. Using a modification of the Tris-
tricine-urea-SDS-PAGE gel system [41], we could resolve the
products of the wild-type and mutant proinsulin alleles under
Figure 4. Co-expression of mutant proinsulins with proinsulin-WT and an unrelated secretory protein demonstrates protein-
specific dominant-negative inhibition of proinsulin export. A. A Myc-epitope tag was inserted into the C-peptide of human proinsulin-WT to
form the construct known as hProCpepMyc, whose peptide sequence is shown. B. 293T cells were transfected to express either human proinsulin or
hProCpepMyc. At 48 h post-transfection, cells were pulse-labeled with
35S-amino acids for 1 h and chased for 1 h. Cell lysates (‘C’) and chase media
(‘M’) were immunoprecipitated with anti-insulin or anti-myc antibodies. There was no recovery of untagged proinsulin-WT with anti-myc antibodies
in either cells or medium (not shown). Immunoprecipitates were analyzed by nonreducing Tris-tricine-urea-SDS-PAGE and fluorography. Note that
hProCpepMyc is secreted efficiently and is recovered equally with anti-insulin and anti-myc immunoprecipitation, but the protein has a higher
apparent molecular mass than proinsulin-WT. C. 293T cells were triply co-transfected to express hProCpepMyc, mouse proinsulins (as indicated) and
a1-antitrypsin at a plasmid ratio of 2 : 4 : 1, respectively. At 48 h post-transfection, cells were pulse-labeled with
35S-amino acids for 1 h and either
lysed at the zero chase time (‘0’) or chased for 3 h. Cell lysates (‘C’) and chase media (‘M’) were immunoprecipitated with anti-insulin (upper set of
gels) and anti-a1-antitrypsin (lower set of gels). Proinsulin immunoprecipitates were analyzed by Tris-tricine-urea-SDS-PAGE while a1-antitrypsin was
analyzed by conventional SDS-PAGE, both under reducing conditions. Note that while the secretion efficiency of untagged mutant proinsulin and
tagged proinsulin-WT varied, a1-antitrypsin was efficiently secreted in every case.
doi:10.1371/journal.pone.0013333.g004
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we determined from three independent experiments that the single
proinsulin-C(A7)Y allele (driven by the Ins2 promoter) in Akita
islets accounts for 36.1%64.8% of newly-synthesized translation
product immunoprecipitable with anti-insulin (i.e., 63.9% wild-
type translation product). In normal control islets (i.e., 100% wild-
type translation product), absolute recovery of the native disulfide
isomer of proinsulin under nonreduced conditions was incomplete
(79.5% of total), consistent with the observation that unsuccessful
protein production occurs significantly even in the absence of any
misfolding-inducing mutation [42]. However, even when normal-
ized to this control level of misfolding (Fig. 5C bottom panel), in
Akita islets recovery of the native disulfide isomer from the three
wild-type alleles was still less than half of that expected. Thus, the
inefficient delivery of the wild-type proinsulin gene product for
packaging into secretory granules [36] can be explained by
recruitment of wild-type proinsulin into misfolded disulfide-linked
protein complexes (Fig. 5C).
In islet beta-cells, BiP associates with proinsulin [43] preferen-
tially to misfolded forms [44]. When newly-synthesized proinsulin
from pulse-labeled Akita islets was co-precipitated with BiP, almost
nothing was recovered under nonreducing conditions (Fig. 5C).
However, under reducing conditions, not only mutant proinsulin
but also wild-type proinsulin was strongly recovered (Fig. 5C
upper panel). Thus, both from cultured cells and from isolated
islets of Akita mice, the data in Figs. 3–5 directly demonstrate that
in MIDY, the presence of the mutant gene product increases
misfolding of the wild-type gene product, which can account for
the onset of insulin deficiency triggering diabetes [28].
Structural features of a MIDY mutant
Proinsulin exhibits an insulin-like core but a disordered C-
peptide domain that renders in vitro structural analyses difficult.
Therefore, structures and stabilities of mutant insulins are typically
used to provide insight into the role of individual residues within
the corresponding proinsulins. We wished to examine how MIDY
mutations might affect the efficiency of peptide chain assembly in
vitro (the ability of isolated B- and A-chains to undergo specific
disulfide pairing), a method that reflects the ability to properly
align cysteine pairings between B- and A-chains. A mutation
Figure 5. MIDY proinsulins cause co-expressed proinsulin-WT to become abnormally engaged in disulfide-linked protein complexes.
A. 293T cells were co-transfected to express human proinsulin-WT and co-express untagged or Myc-tagged proinsulin-C(A7)Y or proinsulin-DelCys,
using a plasmid ratio of 1 : 2. At 24 h post-transfection, the cells were incubated in fresh high glucose DMEM containing 10% FBS for 16 h and media
were analyzed using a human proinsulin-specific radioimmunoassay. Medium collected from cells transfected with empty vectors served as a negative
control; medium collected from cells transfected human proinsulin-WT and mouse proinsulin-WT served as a positive control (ie, set to 100%). Results
are expressed as mean 6 s.d. from at least three independent measurements. Note that presence of the Myc-tag neither caused nor prevented
dominant-negative inhibition of co-expressed human proinsulin-WT. B. 293T cells were co-transfected to express untagged human proinsulin-WT and
co-express Myc-tagged proinsulin-WT or missense mutants, using a plasmid ratio of 1 : 1. At 48 h post-transfection, cells were pulse-labeled with
35S-
amino acids for 1 h, lysed, and immunoprecipitated with anti-insulin followed by analysis under nonreducing (‘NR’) and reducing (‘R’) conditions as
indicated (note that NR and R lanes were run at opposite ends of the gel and upon fluorography were spliced after imaging to juxtapose the two
conditions for each sample). The fractional recovery of co-expressed untagged human proinsulin-WT under nonreducing conditions was compared
against the recovery of the same untagged proinsulin-WT in these samples under reducing conditions (in the Figure, the bands in question connected
by a blue line). With the relative recovery of untagged human proinsulin-WT co-expressed in the presence of tagged proinsulin-WT serving as a positive
control (ie, setto100%), the bargraphbelowquantifies the bands(and the dominant-negative effect)fromthreereplicate experiments.C.Isletsisolated
from wild-type control mice were pulse-labeled with
35S-amino acids for 20 min without chase. The lysates were immunoprecipitated with anti-insulin,
followedbyanalysisundernonreducing(‘NR’)andreducing(‘R’)conditionsasindicated.IsletsisolatedfrommaleAkitamiceweresimilarlylabeled,lysed,
andthe lysates divided for immunoprecipitation with anti-insulinor co-precipitation with anti-BiP.Under reducing conditions, the wild-type andmutant
gene products of Akita islets could be separated and their full recovery quantified. Under nonreducing conditions, the recovery of the native disulfide
isomerofwild-type proinsulin was calculated relativeto totalrecoveryofthewild-type gene product underreducing conditions.Note that thewild-type
translation product is the fastest band on the nonreducing gel and the slowest band on the reducing gel (also note that NR and R lanes were run at
opposite ends of the gel and upon fluorography were spliced after imaging to juxtapose the two conditions for each sample). The bar graph below
quantifies this ratio for wild-type proinsulin in Akita islets relative to that obtained in wild-type (‘WT’) islets 6 s.d., from three independent experiments
(p,0.05 compared to wild-type islets). At right, recombinant human proinsulin-WT or -C(A7)Y were expressed and labeled in 293T cells to serve as
molecular mass markers for the positions of these proteins under reducing conditions.
doi:10.1371/journal.pone.0013333.g005
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not impair insulin chain assembly, and mutations at B24 give rise
to only relatively small (2- to 4-fold) decrements in insulin yield
[45]. However, upon co-incubation of wild-type A- chain with B-
chain bearing the G(B23)V substitution, the insulin product yield
(followed by mass spectrometry, reverse-phase high-performance
liquid chromatography, or insulin receptor binding) was pro-
foundly inhibited, below the limits of sensititvity (,2% of that of
wild-type B-chain), indicating a strong block to interchain disulfide
pairing.
To proceed further with biophysical studies of insulin-G(B23)V,
we exploited a well-studied monomeric, bioactive insulin prefolded
with native disulfide pairs already in place (known as ‘DKP-
insulin’ [46]) to serve as a polypeptide scaffold for replacement of
B23-B30 [47] with a new octapeptide bearing the G(B23)V MIDY
mutation (Fig. 6A, a ball and stick cartoon highlights local
positioning and rotation of residue B23 within the B20-B23
stretch). At high protein concentration, NMR peak broadening for
the G(B23)V mutant suggested an increased predisposition for
protein aggregation as compared to mutants classically associated
with adult-onset diabetes (Fig. 6B). However at low protein
concentration, attenuation of chemical shifts observed in 2D-
NMR spectra suggested only very limited perturbation in local
structure at the carboxyl-terminus of the B-chain (Fig. 6C) and a
native-like pattern of local A-chain structure (Fig. 6D). Moreover,
when prepared within this prefolded insulin template, the
G(B23)V substitution had normal thermodynamic stability based
on resistance to chemical denaturation (not shown). The fact that
minor perturbation of final insulin structure caused by G(B23)V
substitution is greatly outweighed by major defects in the ability to
assemble the insulin chains with proper cysteine pairings indicates
that this MIDY mutant is blocked primarily in the protein folding
pathway rather than in the stability of the insulin native state.
We also looked for a potential structural basis for the surprising
intermediate secretory phenotype and partial dominant-negative
phenotype (Figs. 1, 3, 5, and Figure S1) exhibited by the
Figure 6.
1H-NMR analysis of mutant insulins. A. Expanded ball-and-stick model of the b-turn from residues B20-B23, highlighting positive w
angle at B23 (circular arrow at left). The Ca atom of Gly
B23 is shown in red; amide nitrogen atoms are shown in blue. B.
1H-NMR spectra of DKP-insulin
analogs in D2O (pD 7.0): top to bottom, the MIDY mutant Val
B23 (protein concentration 70 mM), Val
B23 (protein concentration 500 mM); the remaining
spectra were obtained at a protein concentration of 500-600 mM: Leu
B25-DKP-insulin, Leu
A3-DKP-insulin, and DKP-insulin (parent spectrum). The
aliphatic region is shown at right, and aromatic region at left; aromatic spin systems of Phe
B24 and Tyr
B26 are indicated. (C. and D.) Histograms of
NMR parameters, highlighting MIDY-associated perturbation. For each of DKP-insulin (‘‘wt’’), Leu
A3-DKP-insulin, Leu
B25-DKP-insulin, and Val
B23-DKP-
insulin, black and gray bars correspond to A-chain probes and B-chain probes, respectively. A-chain probes [A2(c’,d), A10(c’,d), and A19(d,e)] reflect its
helix-turn-helix conformation (see Table S1) whereas B-chain probes [B15(d), B24(d,e,j), and B26(d,e)] monitor conformation of the C-terminal b-strand
and its packing against the central B-chain a-helix (Leu
B15). C. Normalized secondary chemical shifts changes (scs; defined as differences between
observed chemical shifts and those tabulated from random-coil values). Significant attenuation of chemical shifts is observed only for the MIDY
mutant Val
B23-DKP-insulin. A- and B-chain (black and gray bars, respectively) represent mean scs values of A- and B-chain probe resonances (ND, not
determined). D. Line widths of the above A-chain or B-chain resonances in corresponding 2D-TOCSY spectra (Figure S2) were normalized by the line
widths of corresponding resonances in the wild-type spectrum. Significant peak broadening was observed only in the spectrum of Val
B23-DKP-insulin,
which became more severe as the protein concentration was increased to 500 mM. At 500 mM Val
B23-DKP-insulin exhibits generalized broadening
indicative of protein aggregation; only resonances from A19(d,e) and B26(d,e) could be used to quantify line widths because the other probe
resonances were either too broad or unresolved. B23 bars thus under-estimate extent of resonance broadening.
doi:10.1371/journal.pone.0013333.g006
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only with adult-onset diabetes. Notably, we found that whereas the
solution structures of insulin-F(B25)L and -V(A3)L are essentially
identical to wild-type and cause only trivial decrements in
thermodynamic stability (DDGu 0.2 and 0.5 kcal/mole, respec-
tively), computer modeling from NMR spectroscopic data [48]
revealed that the F(B24)S mutation results in surprising variation
(ie, instability) in the structural coordinates for residues B20-B30
consistent with perturbation C(B19)-C(A20) alignment (Figure S3);
and the insulin-F(B24)S mutant exhibits increased sensitivity to
guanidinium hydrochloride denaturation (DDGu 1.2 kcal/mole).
These results suggest a range of severity of MIDY phenotypes that
are linked to a continuum of severity of protein folding defects.
ER stress response caused by MIDY mutants
Proinsulin misfolding, as occurs in MIDY, is associated with ER
stress [5,15,16,17,35]. We asked whether ER stress and ER stress
response can by itself efficiently block wild-type proinsulin
trafficking. We found that co-expression of the Hong Kong-null
mutant of a1-antitrypsin, which itself is blocked in the secretory
pathway (Fig. 7A upper panels) and is known to induce ER stress
[49], could not block concomitant secretion of wild-type proinsulin
(Fig. 7A lower panels). ER stress response pathways (PERK%pho-
spho-eIF2a%ATF4; ATF6 activation; and Ire1%XBP1 mRNA
splicing) positively regulate BiP transcription [50,51,52,53]; and
indeed, overnight treatment of cells with 0.1 mg/mL tunicamycin
activates ER stress response as confirmed by a BiP promoter-firefly
luciferase reporter [54] (Fig. 7D). Nevertheless, we found that this
too could not block secretion of wild-type proinsulin (Fig. 7C, E).
Nevertheless, expression of MIDY mutants did induce ER stress
in pancreatic beta cells. At 48 h after transfection of Min6 cells,
each of the examined MIDY mutants induced BiP-luciferase
activity relative to wild-type proinsulin (Fig. 8A). Neither
expression of the proinsulin-G(C28)R variant nor the mutants
classically associated with adult-onset diabetes [F(B25)L or
V(A3)L] activated the ER stress response in pancreatic beta cells,
whereas proinsulin-F(B24)S generated an ER stress response that
was intermediate between that of wild-type proinsulin and that
observed for MIDY mutants (Fig. 8A).
For a more precise analysis, we compared the ER stress
response generated by proinsulin-DelCys to that of proinsulin-
C(A7)Y as a positive control [5,35], with BiP promoter-luciferase
activity normalized directly to the steady-state levels of hProC-
pepMyc-DelCys versus hProCpepMyc-C(A7)Y in Min6 cells. We
found that hProCpepMyc-DelCys caused significant ER stress
(Fig. 8B) although it was ineffective as a dominant-negative
inhibitor of wild-type proinsulin transport (Fig. 5). Whereas
perturbation of the proinsulin folding pathway is central to the
blockade of co-expressed wild-type proinsulin in MIDY, the data
indicate that ER stress and ER stress response alone is not
sufficient to account for the observed dominant-negative effects.
Discussion
In the present study we have endeavored to understand the
molecular basis for the onset of insulin deficiency in the syndrome
of Mutant INS-gene-induced Diabetes of Youth (MIDY) [10,11].
Proinsulin mutants causing the MIDY syndrome are distinct both
from insulinopathies previously described as associated with adult
onset-associated diabetes [3] and from recessive alleles that result
in neonatal diabetes through reduced insulin expression [18].
Unequivocally, MIDY mutations cause misfolding of mutant
proinsulin, blocking its progression to insulin [4,5,15] (this report,
Figure S1), and activating ER stress response pathways
[5,15,16,17,35] (this report, Fig. 8).
A prevailing hypothesis is that ER stress-mediated death of
pancreatic beta cells with a resultant loss of beta cell mass triggers
diabetes onset in MIDY [23]. Indeed, in Akita mice, there is little
dispute that ultimately, after diabetes progresses, there is a
significant loss of beta cell mass [29]; presumably this is the case
in human MIDY, just as is the case in type 2 diabetes
[26,55,56,57]. However, decreased insulin production and diabe-
tes in Akita mice, which is linked to inadequate wild-type proinsulin
delivery to secretory granules [36], may occur before there is any
loss of pancreatic beta-cell mass [30]. We now find that misfolding
of the wild-type gene product is induced by the presence of the
mutant gene product. Additionally, regardless of whether such
mutations result in the loss, or creation, of an extra unpaired
cysteine within proinsulin, we find that Cys residues play a critical
Figure 7. ER stress and ER stress reponse alone do not block wild-type proinsulin secretion. A. Wild-type proinsulin secretion from cells
co-expressing wild-type a1-antitrypsin (‘‘wt-AAT’’) or mutant Hong Kong-null a1-antitrypsin (‘‘HKN AAT-myc’’). 293T cells co-transfected with
proinsulin and wt-AAT (left panels) or HKN AAT-myc (right panels) were pulse-labeled with
35S-amino acids and chased for the times indicated. Cell
lysates and media were immunoprecipitated with anti-AAT (upper panels) or anti-insulin (lower panels) and analyzed by SDS-PAGE and fluorography.
During the chase, wt-AAT shifted upwards to a Golgi-glycosylated form and was secreted from cells (‘‘C’’) to medium (‘‘M’’); proinsulin was secreted in
parallel. B. Quantification at 2.5 h of chase of the percent of proinsulin recovered in the medium, from three independent experiments. C. 293T cells
co-transfected with proinsulin, BiP-luciferase, and CMV-Renilla luciferase were treated with tunicamycin (‘TUN’, 0.1 mg/mL) for 16 h. At this time, the
cells were pulse-labeled with with
35S-amino acids for 30 min and chased for 2.5 h. The media were collected and cells were lysed and analyzed by
immunoprecipitation with anti-insulin (the proinsulin band is shown). D. The ratio of simultaneous BiP-firefly to CMV-renilla luciferase activities are
quantified from the experiment shown in panel C. E. At 2.5 h of chase from two independent experiments like that shown in panel C, the percent of
total proinsulin recovered in the medium is expressed as mean 6 s.d.
doi:10.1371/journal.pone.0013333.g007
Mutant INS-Gene and Diabetes
PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13333role in the dominant-negative blockade of insulin production from
the wild-type allele. Furthermore, while each of the MIDY mutants
does cause ER stress and ER stress response, we find that ER stress
and ER stress response alone cannot efficiently block insulin
production from wild-type proinsulin and thus do not appear
sufficient to account for the initiation of insulin deficiency.
Whereas a previous study using a two-dimensional non-
reducing/reducing gel system failed to obtain evidence that the
Akita mutant proinsulin promoted formation of aberrant disulfide
bonds [34], we believe that a simpler, single-dimensional system of
analysis results in a more robust assay [33,36]; demonstrating that
MIDY mutants are predisposed to form aberrant disulfide-linked
protein complexes (Fig. 1A) and that MIDY mutants exhibit
selective perturbation of the intracellular trafficking of co-
expressed wild-type proinsulin (Fig. 3, 4C). This dominant-
negative action precedes impairment of cellular ATP production
or cell viability as it occurs in living cells that are translating and
secreting proteins. Thus, we conclude that the following events are
among the earliest in the molecular pathogenesis of MIDY.
Specifically, shortly after expressing any of the MIDY mutants, the
general ER export pathway for secretory proteins remains
functional (Fig. 4C) even as wild-type proinsulin begins to be
recruited in abnormal disulfide-linked protein complexes (Fig. 5B,
C), impairing its delivery to secretory granules (Fig. 3A) and
thereby impairing wild-type insulin secretion (Fig. 3B). This series
of defects appears sufficient to account for insulin deficiency that is
already in evidence on postnatal day 1 in Akita mice (for review,
see [11]).
Our evidence favoring increased recruitment of wild-type
proinsulin into aberrant disulfide-linked proinsulin-containing
protein complexes, which serves to entrap wild-type proinsulin
within the ER, is highly reminiscent of results from recent studies
perturbing endogenous level of ERO1-beta (the endocrine
pancreas-specific disulfide oxidase) [13]. In these knockout mice,
a diabetic phenotype is linked to abnormally-increased proinsulin
recruitment into interchain disulfide-linked adducts within the ER
of pancreatic beta cells, accompanied by deficient proinsulin
delivery to secretory granules for production of mature insulin
[13]. These findings point strongly to the idea that perturbation of
the proinsulin folding pathway, with or without mutations in the
proinsulin coding sequence, is sufficient to trigger diabetes onset.
While it may be easy to dismiss as trivial the structural basis for
aberrant intermolecular thiol attack by MIDY mutants that add or
remove a cysteine (Fig. 2), it is more challenging to obtain data
providing structural evidence for why non-cysteinyl proinsulin
mutants are also predisposed to form aberrant disulfide-linked
protein complexes in vivo (Fig. 1). In one particular example studied
in detail, we examined insulin-G(B23)V chemically-synthesized
from an insulin scaffold with native disulfide bonds already in place.
Remarkably, insulin-G(B23)V has a largely native structure (Fig. 6)
with essentially normal thermodynamic stability — even as the
isolated B-chain bearing G(B23)V was essentially completely
blocked in assembly with the A-chain to yield insulin. Since chain
alignment leading to interchain disulfide bond formation is the crux
ofthechain-assemblyassay,thedata stronglysuggestthatthereisan
inability to create interchain disulfide pairing, and this kinetic
blockade in the folding of the insulin chains (rather than instability
of the native state) leads to enhanced cysteine thiol exposure that
can promote intermolecular attack. Thus far, structural analyses of
non-cysteinyl MIDY mutants remain quite limited. Nevertheless,
Figure 8. MIDY mutants induce ER stress in pancreatic beta cells. A. Min6 cells were transiently transfected with the BiP promoter-firefly
luciferase plasmid, the pRL-CMV-driven Renilla luciferase reference plasmid, and empty vector or proinsulin expression plasmids at ratio 1 : 2 : 5 (this
ratio helps ensure that BiP-luciferase serves as a reporter from cells synthesizing exogenously expressed proinsulins). At 48 h post-transfection, the
cells were lysed and a ratio of firefly/renilla luciferase was measured. The relative activity of the BiP promoter in cells expressing mutant proinsulins
was compared to that in cells expressing wild-type (‘‘WT’’) proinsulin, which served as a negative control. In a separate co-transfection Min 6 cells
were treated overnight with tunicamycin (‘Tun’, 1 mg/mL), which served as a positive control for ER stress induction. Results are expressed as mean 6
s.d. from at least four independent experiments. *,0.05 compared with proinsulin-WT B. Min6 cells were co-transfected to express BiP-luciferase and
either hProCpepMyc-C(A7)Y or hProCpepMyc-DelCys. At 48 h after transfection, the cells were lysed and BiP-luciferase activity was measured along
with the steady-state level of proinsulin mutants by Western blotting with anti-myc. Neither mutant is secreted by from the cells to the medium; note
that DelCys is not deficient for induction of ER stress response.
doi:10.1371/journal.pone.0013333.g008
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mutations act as kinetic blocks in the folding pathway to proinsulin
disulfide bond formation, resulting in free thiol availability that is a
key to the molecular pathogenesis of MIDY.
In support of this hypothesis, we find that proinsulin-DelCys —
despite being the most misfolded of all proinsulin mutants and
completely blocked within the secretory pathway — cannot induce
recruitment of co-expressed wild-type proinsulin into aberrant
protein complexes (Fig. 5), cannot efficiently impair intracellular
transport of co-expressed wild-type proinsulin (Fig. 4C) and thus
cannot block insulin production or secretion (Fig. 3). These
findings emphasize that at least one Cys residues is required for
efficient dominant-negative blockade of insulin production from
the wild-type allele, leading to an unfavorable chain of molecular
events that results in progressive ER stress and beta cell failure.
Unmistakably, ER stress and ER stress response are important
consequences of proinsulin retention in the ER (Fig. 8A).
However, ER stress and ER stress response alone cannot
efficiently block production of insulin from wild-type proinsulin
(Fig. 7). Thus it is not clear that ER stress, ER stress response, and
loss of beta cell mass can account for initial pancreatic insulin
deficiency that leads to the onset of diabetes in Akita mice, a model
of MIDY.
In MIDY, the severity of phenotypes may be linked to the degree
of folding (and secretion) disturbance [16,17]. Of the mutations
classically associated with adult-onset diabetes [1,3], curiously,
proinsulin-F(B24)S exhibits a more perturbed distal B-chain
structure (Figure S3), a twofold decrease in insulin yield from
the chain-assembly assay, a partial defect for secretion (Figure
S1A), partial engagement in disulfide-linked protein complexes in
the ER (Fig. 1), a partial dominant-negative effect on insulin
production (Fig. 3), partial recruitment of wild-type proinsulin into
disulfide-linked complexes (Fig. 5B), and partial activation of ER
stress response (Fig. 8A). Loss of F(B24) may de-stabilize the
native-like cluster of hydrophobic side chains near C(B19) and
C(A20), decreasing the efficiency of disulfide pairing [58]. These
findings appear consistent with a spectrum in the molecular
pathogenesis of early-onset and late-onset diabetes caused by
autosomal dominant INS gene mutations, ranging all the way to
proinsulin-G(C28)R [7] which ultimately generates perfect human
insulin lacking any mutation, does not use the MIDY mechanism
(this report) and instead operates either through novel mechanisms
involving the mutant C-peptide [15] or is coincidental to the
pathogenesis of diabetes.
In summary, we have defined the molecular pathogenesis of
MIDY as a syndrome in which mutant proinsulins use unpaired
cysteine residues to recruit nonmutant proinsulins into disulfide-
linked complexes, blocking insulin production that leads to insulin-
deficiency, beta cell ER stress, and diabetes. Uncovering the
earliest events in the molecular mechanism of the disease may help
in identifying therapies designed to rescue proinsulin folding in the
ER of pancreatic beta-cells.
Materials and Methods
Materials
Guinea pig anti porcine insulin antibody, Rat insulin radioim-
munoassay (#RI-13K), human insulin-specific radioimmunoassay
(#HI-14K) and human proinsulin specific radioimmunoassay
(#HPI-15K) were from Millipore; rabbit anti-Myc antibody was
from Immunology Consultants Labs; Zysorbin was from Zymed;
[
35S] amino acid mixture was from from ICN; DTT, Protein A
agarose, and ‘RIA-grade’ BSA were from Sigma; 4-acetamido-49-
maleimidylstilbene-2,29-disulfonic acid (AMS), Met/Cys-deficient
DMEM (Dulbecco’s modified Eagle’s medium) and all other tissue
culture reagents were from Invitrogen. Constructs encoding wild-
type and Hong Kong-null a1-antitrypsin-myc were the kind gifts of
Dr. R. Sifers (Baylor College of Medicine, Houston TX).
Proinsulin mutagenesis and construction of
hProCpepMyc and mouse ProCpepMyc
The mouse Ins2 cDNA was amplified by RT-PCR from total
RNA of isolated mouse islets, ligated into the pGEM T-vector and
sequenced. Ins2 cDNA was then cloned into pCMSGFP and the
resulting plasmid was used as a template to introduce mutations
associated with human diabetes, using the QuikChange site-
directed mutagenesis kit (Stratagene). For proinsulin-DelCys, the
C(A6) and C(A11) positions were mutated to methionine, C(A7)
was mutated to tyrosine, and C(B7), C(B19) and C(A20) were each
mutated to serine. Human preproinsulin cDNA was subcloned
into pTarget (Promega) and the mutations were introduced as
described above. A Myc-epitope was inserted into human or
mouse C-peptide using following primers: human preproinsulin
cDNA: 59- GCAGGTGGAGCTGGGCGGGGGCCCTGAAC-
AGAAGCTGATCTCAGAGGAGGACCTGGGTGCAGGCAG-
CCTGCAGCCCTTG-39 and 59-CAAGGGCTGCAGGCTGC-
CTGCACCCAGGTCCTCCTCTGAGATCAGCTTCTGTTC-
AGGGCCCCCGCCCAGCTCCACCTGC-39; mouse preproin-
sulin cDNA: 59-CAACTGGAGCTGGGTGGAGGCCCGGAA-
CAGAAGCTGATCTCAGAGGAGGACCTGGGAGCAGGTG-
ACCTTCAGACCTTG-39 and CAAGGTCTGAAGGTCACC-
TGCTCCCAGGTCCTCCTCTGAGATCAGCTTCTGTTCC-
GGGCCTCCACCCAGCTCCAGTTG). Mutations were con-
firmed by DNA sequencing.
Cell culture
INS832/13 rat insulinoma cells were kindly provided by Dr. C.
Newgard (Durham, NC). Cells were cultured in RPMI 1640
supplemented with 10% FBS, 10 mM Hepes, 1 mM sodium
pyruvate, penicillin-streptomycin and 50 mM 2-mercaptoethanol
(Sigma). Min6 mouse insulinoma cells were cultured in DMEM
supplemented with 10% FBS, penicillin-streptomysin and 50 mM
2-mercaptoethanol. 293T (human embryonic kidney-derived) cells
were cultured in DMEM supplemented with 10% FBS and
penicillin-streptomycin.
Transfection of cells, metabolic labeling, and
immunoprecipitation
293T cells were plated into 6 or 12-well plates 1 d before
transfection. A total of 1–2 mg plasmid DNA was transfected using
Lipofectamine (Invitrogen). Cells were pulse-labeled with
35S-
labeled amino acids 48 h after transfection and chased for the
times indicated. A proteinase inhibitor mixture was added to cell
lysates and chase media. The samples were precleared with
Zysorbin and immunoprecipitated as described in the text. Anti-
insulin or anti-Myc immunoprecipitates were boiled for 5 min in
gel sample buffer [1% SDS, 12% glycerol, and 0.0025% Serva
Blue in 50 mM Tris (pH 6.8) with or without 100 mM DTT] and
analyzed using tris-tricine-urea-SDS-PAGE under nonreducing or
reducing conditions [59]. Immunoprecipitates of a1-antitrypsin
were boiled for 5 min and resolved by conventional Laemmli SDS
10%-PAGE.
Radioimmunoassay and Western blot analysis of
secretion of mutant proinsulins
To examine secretion of mutant proinsulin beginning at 24 h
after transfection, medium was replaced with serum free high-
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were collected and secreted proinsulins were measured using anti-
rat insulin radioimmunoassay, which recognizes both human and
mouse proinsulin and insulin. For hProCpepMyc constructs,
transfected cell lysates and media samples were analyzed by
Western blotting with anti-myc antibodies.
Radioimmunoassay of secreted wild-type human
proinsulin and insulin
293T cells were co-transfected with wild type human pre-
proinsulin and mouse wild type or mutant preproinsulin at a DNA
ratio of 1:2. Beginning at 24 h after transfection, medium was
replaced with high-glucose DMEM plus 10% FBS and further
incubated for 16 h. The media were collected and secreted human
wild type proinsulin was measured using human-specific proinsulin
radioimmunoassay. Media collected from 293T cells transfected
with wild type mouse proinsulin was used as negative control for
radioimmunoassay specificity. INS-1 cells were similarly co-
transfected using Lipofectamine 2000 (Invitrogen) at a DNA ratio
of 1:3. Cells were trypsinized 24 later and re-plated in triplicate
wells. After 28 h incubation, media were then collected to measure
human insulin specifically by radioimmunoassay.
Alkylation of proinsulin Cys thiols
Immunoprecipitated proinsulin was resuspended and incubated
in a buffer containing 2% SDS, 50 mM Tris pH 7.4 with or
without 10 mM AMS for 1.5 h at 37uC. The reaction was stopped
by boiling in SDS sample buffer plus 0.1 M DTT before analysis
by Tris-tricine-urea-SDS-PAGE.
Steady-State human insulin content of INS-832/13 cells
transiently expressing mutant mouse proinsulin
INS-832/13 cells were transfected with mouse mutant proin-
sulin 1 day after plating using Lipofectamine (3 mg of plasmid
DNA per well of a six-well plate). After 48 h, transfected cells were
trypsinized, washed, resuspended in PBS and isolated by
fluorescence-activated cell sorting. A total of 100 ml of acid-
ethanol was used to extract insulin from each set of sorted INS-
832/13 cells. Processed human insulin was measured in the
extracts using a human insulin-specific radioimmunoassay.
BiP promoter-driven luciferase assay
Min6 cells were plated into 24-well plates 1 d before
transfection. Using Lipofectamine 2000 (Invitrogen), cells were
co-transfected with pBiP-firefly-luciferase reporter plasmid [54]
(provided by Dr. R. Kaufman,University of Michigan, Ann
Arbor), CMV-renilla-luciferase plasmid (Promega), and human
wild type or mutant proinsulin at a DNA ratio of 1:2:5,
respectively. At 48 h post-transfection, cell extracts were prepared
for the dual-luciferase reporter assay (Promega) with BiP-luciferase
normalized to Renilla luciferase activity.
Isolation and metabolic labeling of mouse pancreatic
islets
Using Akita mice and wild-type littermates, islets were isolated
and recovered overnight as described previously [36]. In each
case, 50 islets were washed twice in prewarmed Met/Cys-deficient
medium plus 1% BSA and 10 mM Hepes, pH 7.35. Islets were
then pulse-labeled with
35S-labeled amino acids in the same
medium for 20 min. After labeling, islets were directly immersed
in lysis buffer containing a proteinase inhibitor mixture,
immunoprecipitated with anti-insulin, and analyzed by Tris-
tricine-urea-SDS-PAGE under both nonreducing and reducing
conditions.
Statistical analysis
Statistical analyses were carried out by ANOVA followed by
Bonferroni’s Multiple Comparison Test using GraphPad Prism 5.
Data are presented as means6SD. A P value of ,0.05 was taken
as statistically significant.
Synthesis of insulin analogs
Human insulin was obtained from Novo-Nordisk (Copenhagen,
DK). H(B10)D-insulin and H(B10)D-des-octapeptide[B23-B30]-
insulin were obtained from Eli Lilly Co. (Indianapolis, IN).
Synthesis of variant B-chains, insulin chain assembly, and protein
purification were performed as described [60,61]. Selected B-
chain analogs contained three ‘‘DKP’’ substitutions to prevent self-
association of insulin [H(B10)D, P(B28)K, and K(B29)P]. V(A3)L-
DKP-insulin was prepared by chain assembly. G(B23)V-DKP-
insulin and F(B25)L-DKP-insulin were prepared by semisynthesis
[62] beginning with H(B10)D-des-octapeptide[B23-B30]-insulin
and corresponding C-terminal octapeptides (VFFYTKPT or
GFLYTKPT, respectively). Preparation of F(B24)S-insulin has
previously been described [48].
1H-NMR Spectroscopy
Spectra were obtained at 600 and 700 MHz in aqueous solution
at pH 7–8 at 25u and 32uC and in 20% deuterioacetic acid at
25uC as described [63,64]. DG/RMD calculations were per-
formed as described [61].
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0013333.s001 (1.28 MB
DOC)
Figure S1 Test for secretion of mutant proinsulins known to be
associated with human diabetes. 293T cells were transfected with
vector alone or the same plasmid bearing wild-type preproinsulin
(‘WT’) or preproinsulin missense mutants in which the described
mutation is within the B-chain, the C-peptide, or A-chain. A. At
40 h post-transfection, cells were pulse-labeled with 35S-amino
acids for 1 h, and then chased for 1 hour. The media (‘‘M’’) were
collected and cells (‘‘C’’) were lysed. After immunoprecipitation
with anti-insulin the samples were analyzed by nonreducing Tris-
Tricine-urea-SDS-PAGE. B. Transfected 293T cells were divided
in two equal portions. One portion was pulse-labeled with 35S-
amino acids for 30 min (without chase) to examine new synthesis
of proinsulins as measured by immunoprecipitation with anti-
insulin followed by reducing Tris-tricine-urea-SDS-PAGE (lower
fluorogram); the second portion was incubated with high glucose
DMEM containing 0.2% BSA for 16 h and media were analyzed
using a rat insulin radioimmunoassay that cross-reacts with
proinsulins of all species (bar graph above). C. 293T cells
transfected to express hProCpepMyc-WT (as described in Fig. 4
of the main text) or hPCpepMyc-C(A7)Y were incubated for 6 h in
fresh medium before the media were collected and cells lysed.
Equal fractions of cells and media were analyzed by SDS-PAGE,
electrotransfer, and immunoblotting with anti-myc antibodies.
The data highlight that the inability to recover MIDY mutant
proinsulin in the media is unrelated to the specificity of insulin
antibodies used for detection.
Found at: doi:10.1371/journal.pone.0013333.s002 (6.75 MB
TIF)
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insulin and its analogs. Total correlation spectra (TOCSY) are
shown of (A) parent DKP-insulin (for which the positions of highly
reproducible NOEs are shown), (B) V(A3)L-DKP-insulin, (C)
F(B25)L-DKP-insulin, and (D) G(B23)V-DKP-insulin. DKP-insu-
lin contains two substitutions in the dimer interface [P(B28)K and
K(B29)P] and one substitution in the trimer interface [H(B10)D];
its affinity for the insulin receptor is twice that of wild-type insulin.
Spectra were acquired in each case at 25uC with TOCSY mixing
time 55 ms. The chemical shifts of Y(A14) provides a sensitive
marker of A-chain folding as it projects from the back surface of
insulin, and the ortho-meta resonance of F(B24) provides a
sensitive marker of folded state of the B-chain b-strand (B24–B28)
due to its wild-type packing against C(B19) and L(B15), associated
with an upfield resonance position in native-like structures (blue
cross peaks in panels A–C). The insulinopathies V(A3)L and
F(B25)L, which are classically associated with adult-onset diabetes,
do not perturb the native fold of B- or A-chains; the MIDY
substitution G(B23)V in a DKP-insulin in which disulfide bonds
are already intact results in attenuation of resonances of F(B24)
(red in panel D) and F(B25) (green in panel D) indicating local
structural perturbation in the B-chain. Asterisks indicate altered
cross-peak position of Y(B16) due to the absence of the F(B25) ring
current (panel C) or altered positioning of the aromatic-rich b-
strand (B24-B28) adjoining G(B23)V (panel D). Protein concen-
trations were 500–600 mM except for G(B23)V-DKP-insulin,
which was diluted to 70 mM to avoid aggregation.
Found at: doi:10.1371/journal.pone.0013333.s003 (10.45 MB
TIF)
Figure S3 Solution structures of insulin analogs. (A) Ensemble of
NMR-derived structures of DKP-insulin (Hua QX, et al., J. Mol.
Biol. 264, 390–403 (1996)). The A- and B-chains are shown in
light and dark gray, respectively. (B–D) Solution structures of
V(A3)L-DKP-insulin (B), F(B24)S-insulin (C), and F(B25)L-DKP-
insulin (D). In each case the mutant side chain is shown in red.
Whereas V(A3)L is compatible with native-like structure in accord
with results of X-ray crystallography (Wan Z-L, et al., Biochem-
istry 44, 5000-16 (2005)), F(B24)S destabilizes the C-terminal
strand of the B-chain (Hua QX, et al., Proc. Natl. Acad. Sci. USA
90, 582-6 (1993)). (D) The solution structure of F(B25)L-DKP-
insulin is essentially identical to that of DKP-insulin; differences in
precision are likely to reflect extent of NMR analysis pursued
under different conditions and not actual underlying differences in
structure or dynamics. The solution structure of G(B23)V-DKP-
insulin could not be obtained due to aggregation at protein
concentrations amendable to the current NOESY analysis.
Found at: doi:10.1371/journal.pone.0013333.s004 (10.47 MB
TIF)
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